Loading clinical trials...
Loading clinical trials...
A Phase 2, Open-Label Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)
Conditions
Interventions
Ixazomib
Daratumumab
+1 more
Locations
28
United States
Pacific Cancer Medical Center
Anaheim, California, United States
Colorado Blood Cancer Institute
Denver, Colorado, United States
SCRI - Florida Cancer Specialists - Panhandle
Tallahassee, Florida, United States
Research Medical Center - Kansas City
Kansas City, Missouri, United States
SCRI - Tennessee Oncology - Nashville - Centennial
Nashville, Tennessee, United States
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Start Date
March 13, 2018
Primary Completion Date
January 1, 2022
Completion Date
June 26, 2023
Last Updated
July 3, 2024
NCT06179888
NCT06152575
NCT04973605
NCT05201781
NCT05862012
NCT06138275
Lead Sponsor
Takeda
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions